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Evidence is growing for the long-term effects of environmental factors during early-life on later
disease susceptibility. It is believed that epigenetic mechanisms (changes in gene function not
mediated by DNA sequence alteration), particularly DNA methylation, play a role in these
processes. This paper reviews the current state of knowledge of the involvement of C1 metab-
olism and methyl donors and cofactors in maternal diet-induced DNA methylation changes
in utero as an epigenetic mechanism. Methyl groups for DNA methylation are mostly derived
from the diet and supplied through C1 metabolism by way of choline, betaine, methionine or
folate, with involvement of riboflavin and vitamins B6 and B12 as cofactors. Mouse models
have shown that epigenetic features, for example DNA methylation, can be altered by peri-
conceptional nutritional interventions such as folate supplementation, thereby changing off-
spring phenotype. Evidence of early nutrient-induced epigenetic change in human subjects is
scant, but it is known that during pregnancy C1 metabolism has to cope with high fetal
demands for folate and choline needed for neural tube closure and normal development. Ret-
rospective studies investigating the effect of famine or season during pregnancy indicate that
variation in early environmental exposure in utero leads to differences in DNA methylation of
offspring. This may affect gene expression in the offspring. Further research is needed to
examine the real impact of maternal nutrient availability on DNA methylation in the devel-
oping fetus.
DNA methylation: C1 metabolism: DOHaD: Methyl donors
The ‘Developmental Origins of Health and Disease’
(DOHaD) hypothesis proposes not only that we are what
we eat but also that we could be what our parents ate, and
is a biologically and evolutionarily fascinating concept.
The hypothesis postulates that early-life development is
critically sensitive to inadequate nutrition and other environ-
mental factors leading to permanent changes in metabolism
that can alter susceptibility to complex diseases(1). These
early-life exposures can thereby be recorded and archived
in the ‘cellular memory’, by inducing persistent adapta-
tions in cellular function(s) with long-term effects(2). Not
only is this process of scientific importance, it also has
relevance for public health, particularly in the framework
of the twenty-first century pandemics of chronic diseases:
the implication being that improvements in nutrition of one
generation could prevent common complex diseases in
future generations(3).
The foundations of the DOHaD theory were first
formulated after Professor David Barker and colleagues
from the MRC Environmental Epidemiology Unit in
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Southampton (UK) studied retrospective data of
geographical disease distribution and noticed that neonatal
mortality was strongly associated with IHD rates in the
UK(4). Almost 30 years on, evidence has been extensively
documented for a wide number of complex diseases includ-
ing hypertension(5), type 2 diabetes(6) and cancers(7). Yet,
the mechanisms involved have not been fully elucidated.
This review discusses the current state of evidence that
DNA methylation may be an important mediator of fetal
programming in response to alterations in maternal diet
and nutritional status during pregnancy, thus affecting later
phenotypic outcomes.
The case for DNA methylation
The capacity for developmental plasticity likely requires
many mechanisms to interact and current evidence sug-
gests epigenetic mechanisms play an important role in this
process(8). Epigenetics refers to a number of mechanisms
(namely DNA methylation, histone modification and RNA-
related epigenetic marks) that establish layers of informa-
tion in addition to DNA sequence information. They result
in the ‘epigenome’ and lead to mitotically (and sometimes
meiotically) replicable changes in gene expression poten-
tial that are not mediated by DNA sequence alteration(8).
These epigenetic mechanisms ‘crosstalk’ in an orchestrated
manner to regulate gene expression throughout life(9).
Of all the epigenetic mechanisms so far described, DNA
methylation is possibly the best characterised (Fig. 1). This
process involves the covalent addition of a methyl group
(CH3) to the 5
0 position of the pyrimidine ring of the cyto-
sine base within cytosine–guanidine (CpG) dinucleotides,
converting cytosine to 5-methylcytosine. This chemical
modification alters the physical structure of the DNA, pre-
venting DNA-binding proteins access during transcription
processes, ultimately silencing the affected gene(10). CpG
are typically methylated. However, gene promoters contain
CpG-rich DNA areas called ‘CpG islands’, which are
usually unmethylated, highlighting the importance of DNA
methylation in the regulation of gene expression(10,11).
Gene promoters are regulatory regions that contain
transcription-factor binding sites to facilitate the transcrip-
tion of the gene. Methylation in these regions acts as a
gene expression-regulator switch, and thus can ultimately
lead to phenotypic differences(12).
DNA methylation is catalysed by a number of DNA
methyltransferases. The specific details of how these
enzymes operate are unclear, but it is generally accepted
that DNA methyltransferases 3a and 3b are mainly in-
volved in de novo establishment of methylation patterns,
whereas subsequent maintenance is guaranteed by differ-
ent DNA methyltransferase 1 variants(13). The role of DNA
methyltransferase 2 remains undetermined(14).
For any mechanism to be a realistic candidate under-
lying the DOHaD hypothesis some premises should be
met. It should be a molecular mechanism taking an active
part in both prenatal development and the onset of a given
disease. It should also be sensitive to environmental factors
but have the ability to be stable over time. DNA methyla-
tion, as discussed in this review, meets these requirements.
Establishment of DNA methylation
Embryogenesis has been identified as a critical window in
the establishment of the epigenome(8). Gamete genomes
are highly methylated when compared with somatic
cells(11). However, upon fertilisation, the newly formed
zygote undergoes global demethylation, followed by
de novo genome-wide methylation after implantation. New
methylation patterns are established from pluripotent cells
Box 1: Glossary 
 
 
 
 
 
• Genome: The complete set of hereditary information 
possessed by an organism.
• Epigenetics: Changes in gene function not mediated 
by DNA sequence alteration
• Epigenome: The complete set of epigenetic informa-
tion possessed by an organism.
• DNA methylation: The addition of methyl groups to 
the cytosine (C) in the DNA chain, thereby regulat-
ing gene expression. 
• Imprinting: Parent-of-origin specific gene expres-
sion, whereby either the paternal or maternal allele is 
silenced.
• Metastable epiallele: DNA loci whose epigenetic 
state is independent of cell differentiation and which 
exhibit dynamic stochasticity.
• Epigenetic transgenerational inheritance: Epigenetic 
modifications that pass to the next generation 
through the gametes.
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Fig. 1. DNA methylation.
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in a lineage-specific manner, through changes in gene ex-
pression leading to differentiation of organs and tissues(8).
The methylation patterns are perpetuated and propagated
with high fidelity during rapid mitotic multiplication in
fetal development(15). However, the rules for the estab-
lishment of these patterns and the sources of individual
epigenetic variation are not fully understood. It is believed
that there are some genetically led patterns(16), while others
are essentially stochastic(17) (Fig. 2). Timing is clearly
critical but in human subjects the details remain largely
undefined.
Classical examples of developmental DNA methylation
are the X chromosome inactivation in women(18) and im-
printing of genes (see box 1 in Fig. 1), such as the IGF2
gene, where the maternal allele is suppressed (imprinted),
while the paternal allele is activated (expressed)(19,20).
Imprinted genes play a critical role in regulation of pla-
cental and embryonic development, as well as in intrau-
terine growth and thus, early influences can have a
substantial impact on human health later in life(10,21).
Imprinting marks are not erased during early embryonic
development(22). Misprogramming of the appropriate
methylation patterns is associated with abnormal physical
and mental development, including a number of ‘epige-
netic’ developmental syndromes such as Beckwith–Wie-
demann syndrome(23,24).
Large-scale erasure of methylation marks during early
development limits the possibility of transgenerational
inheritance, but this may occur through epigenetic marks
that have failed to be erased before implantation or via
epigenetic marks in germ line cells(25). The vast majority
of exposures alter only somatic cells but when epigenetic
modifications occur in the germ line during embryonic
gonadal sex determination, they become permanently pro-
grammed, and then the altered epigenome can appear in
subsequent generations, in a sex-specific manner and in the
absence of further environmental exposures(26,27).
Certain loci, known as metastable epialleles (ME), exist;
their epigenetic state is independent of cell differentiation
and they exhibit dynamic stochasticity(28). At ME, epi-
genotype is established in a probabilistic manner in the
early embryo and maintained thereafter in the differ-
entiated cell lineages. This can lead to permanent pheno-
typic consequences, even in genetically identical
individuals(29), and ME are thought to be particularly vul-
nerable to transient environmental influences(30).
The epigenome, unlike the genome, can be modified in
response to interactions with environmental conditions
within a lifetime. The epigenotype affects an individual
response to a particular environment, and likewise the
environment has the potential to change the epigenetic
landscape, contributing to plasticity of phenotypes(8). DNA
methylation might explain how individuals can respond
relatively quickly to changing external cues, such as dele-
terious compounds (e.g. tobacco or cooking smoke, arsenic
or aflatoxins), infectious agents (e.g. Helicobacter pylori),
or stress, either during development or throughout
life(31,32). Early DNA methylation alterations during cell-
lineage differentiation tend to be irreversible while some
later changes can be reversed(33,34).
DNA methylation depends specifically upon supply of
dietary methyl groups, which are necessary throughout life
to establish methylation patterns and to maintain these dur-
ing repeated cycles of cell proliferation(35). Once the epi-
genome is established, it is less responsive to external
stimuli, but during early development, when tissue-specific
patterns are undergoing establishment and maturation, the
epigenome is sensitive to subtle changes(26). Maternal nu-
tritional deficiency or excess may thus result in permanent
DNA methylation abnormalities (hypo- or hypermethyla-
tion) with the potential to affect gene expression(12).
In contrast to other epigenetic mechanisms, such as trans-
ient histone modifications, DNA methylation marks are
chemically very stable and can be retained over time, thus
potentially explaining long-term consequences for health.
However, the global level of DNA methylation is thought
to change over time and deteriorate due to oxidative stress
and aging(36).
Genetic
variation
Stochastic
events
DEVELOPMENT
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(epimutation in germ cells)
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Fig. 2. Sources of individual epigenetic variation.
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The role of epigenetic dysregulation and particularly of
DNA methylation in the development of human disease
has been increasingly recognised. Aging in human subjects
is known to be associated with global hypomethylation,
resulting in aberrant gene activation and age-related
diseases(37,38). Promoter-specific methylation has been
associated with different diseases(39). The most convincing
evidence has been observed in relation to carcinogen-
esis(40,41), but there is also growing evidence that epigen-
etic dysregulation affects other life-course diseases such as
CVD(42), type 2 diabetes(43) and obesity(44).
Taken together, such evidence supports DNA methyla-
tion as a plausible interface between the prenatal and early
postnatal environment and adult disease risk.
Confirmatory evidence in animal models
Much of what is known to date is based on findings from
animal studies. Murine models have provided direct evi-
dence linking early-life programming through nutritional
exposures with DNA methylation-mediated changes in
gene expression, and hence phenotype(29). Diets supple-
mented in methyl donors given to dams pre-conceptually
and in pregnancy, can lead to permanent changes in gene
regulation and to strong phenotypical modulation in the
context of genetically identical inbred mice(45).
A classic example is the agouti viable yellow mouse,
which has a yellow coat colour and is obese and hyper-
insulinaemic(29). This is caused by a dominant mutation of
the agouti locus, caused by the insertion of a so-called IAP
(intracisternal A particle) repeat element, which acts as an
alternative promoter(46). Such mobile elements render this
genomic region epigenetically labile(29). When this pro-
moter is hypomethylated, it leads to expression of the
agouti gene that regulates the production of yellow pig-
ment and other pleiotropic effects including obesity. When
it is silenced by methylation, the synthesis of yellow pig-
ment is down-regulated and a pseudoagouti coat colour
(darker) is produced(29). Maternal methyl-donor supple-
mentation (e.g. with folic acid, vitamin B12, or betaine
(45))
was confirmed to cause hypermethylation of the agouti
viable yellow gene in the offspring, affecting offspring
phenotype in a dose-dependent fashion. This genetic locus
is considered an ME where methylation patterns are
established stochastically within litter mates. Therefore,
offspring present with a range of methylation at this locus
and consequently variation in phenotypes, ranging from
obese hyperinsulinaemic yellow, heavily to slightly yellow
mottled and leaner non-hyperinsulinaemic pseudoagouti
phenotypes. Other examples are known, such as the Axin
fused gene that has a similar epigenetic behaviour, either
leading to the expression or not of a kinked tail(47,48).
Furthermore, epigenetic transgenerational inheritance has
been observed at ME in mice(49,50).
Research has also been conducted in sheep(51). Ewes
with restricted dietary methyl donors at physiological
ranges, starting 8 weeks prior to conception until 6 d after
conception, showed no effects in pregnancy establishment.
However, offspring, and especially male descendants, had
low weight at birth and were heavier and fatter in adult-
hood. They also had altered immune responses, were
insulin resistant and had elevated blood pressure. Liver
DNA methylation assessment showed altered widespread
methylation status, in 4% of 1400 CpG islands examined.
More than half of the affected loci were specific to males.
These animal models confirm the biological plausibility
discussed earlier, and make it reasonable to think that simi-
lar processes could operate in human subjects.
Supply of methyl groups for DNA methylation
Methyl groups for fetal DNA methylation and develop-
ment are provided through C1 metabolism
(52). Pregnancy
and lactation are times when methyl-donor supply is cri-
tical and demand for nutrients is higher(35). The transfer
of methyl groups depends ultimately on the availability of
S-adenosyl-methionine (SAM). This is derived from
methionine, which is converted through the action
of methyltransferases to S-adenosylhomocysteine (SAH),
while splicing off a methyl group and subsequently to
homocysteine (Fig. 3).
Betaine-dependent remethylation
Diet
Protein
DNA methylation
Transmethylation
Transsulfuration
Cysteine
DMG
SAM
SAH
Homocysteine
Methionine
Betaine
Choline
Tetrahydrofolate
Methyl-
tetrahydrofolate
B12
B6
Folate-dependent remethylation riboflavin
Fig. 3. (Color online) Diagram of C1 metabolism. Methyl donors are shown in orange, functional bio-
markers in green and cofactors are encircled. SAM, S-adenosyl-methionine; SAH, S-adenosylhomo-
cysteine; DMG, dimethylglycine.
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C1 metabolism is characterised by a redundancy of
pathways to conserve methionine that guarantees methyl-
group availability, while removing unwanted homocysteine
excess out of the system(53). Two complementary reme-
thylation pathways, one folate dependent, the other folate
independent, intersect at the methionine cycle for the
transformation of homocysteine into methionine. In the
folate-dependent pathway, tetrahydrofolate is reduced to
methyltetrahydrofolate by methyltetrahydrofolate reduc-
tase, with the intervention of riboflavin. Vitamin B12 cata-
lyses the C1 unit transfer from methyltetrahydrofolate to
methionine by methionine synthase. The alternative folate-
independent pathway is catalysed by the enzyme betaine
homocysteine methyltransferase using betaine direct from
the diet or from choline. In addition, homocysteine can be
transformed into cysteine in certain tissues (liver, kidneys,
pancreas, intestine and brain) by irreversible transsul-
phuration, in a process that requires vitamin B6.
Clear interdependence exists between these two path-
ways, and perturbing the metabolism of any of the individ-
ual elements results in compensatory mechanisms via the
alternative pathway(54) or in elevated plasma homocysteine
concentrations(55,56). The specific functioning of fetal C1
metabolism is difficult to study, although it has been re-
ported that the activities of methyltetrahydrofolate reduc-
tase and methionine synthase in preterm infant tissues were
higher than those full-term or young children(57). There-
fore, prospective studies to investigate the role of maternal
nutrition on the offspring DNA methylation need to be
based on robust biomarkers for maternal C1 metabolism.
Functional biomarkers of methylation capacity
Homocysteine, SAM, SAH and dimethylglycine are of
metabolic origin and usually a good reflection of the
overall status, i.e. excess or deficiency of substrates and
cofactors within the C1 metabolism
(12,58). DNA methyla-
tion is dependent on the balance between the substrate
supply (SAM) and removal of the product (SAH), which is
a potent inhibitor of SAM-dependent methyltransferase
activity(59) and thereby methylation by way of a negative
feedback loop. Hence, the clearing of SAH is the key for
adequate methylation. The SAM:SAH ratio, sometimes
called the ‘methylation index’, can be used as an indicator
of the methylation potential of an individual(12).
Methylation regulation enzymes are differentially
expressed in human tissues, leading to tissue-specific C1
metabolism and thus tissue-specific homocysteine, SAM
and SAH level regulation and methylation capacity(60). For
this reason, plasma SAM:SAH must be interpreted with
caution and systemic SAM:SAH is not necessarily a
meaningful indicator of tissue-specific methylation poten-
tial. Furthermore, efficiency of SAM transmembrane
transport into the cells appears to be low(61). Cells synthe-
sise SAM from circulating methionine or homocysteine, as
these cross the cell membrane easily. Thus, circulating
homocysteine could be a better indicator of methylation
potential(62). Only the kidney appears capable of taking up
SAH directly from plasma(63). The transsulphuration of
homocysteine to cysteine can alleviate SAM inhibition of
methyltransferases(62).
Homocysteine is a non-protein-forming sulphur-
containing amino acid that may exist free or bound to
cysteine or albumin(64). Elevated homocysteine is a good
and well-studied indicator of C1 metabolism disturbance
and has consistently been associated with low concen-
trations of folate, vitamins B12 and B6, choline and
betaine(65–69). Conversely, a meta-analysis of placebo-
controlled trials of folic acid supplementation showed an
average 25% reduction in homocysteine levels(70).
The Hordaland homocysteine study showed that high
homocysteine concentrations were associated with risks of
pre-eclampsia, premature delivery and low birth weight(71).
High homocysteine denoting aberrant methyl metabolism
in utero is also linked with neural tube defects(72). Usually,
values of 5–15mmol/l are considered normal for plasma
homocysteine concentration, although different cut-off
values have been used to define elevated concentrations(58).
There is a 30–60% decline in plasma homocysteine con-
centrations during pregnancy compared with non-pregnant
women, due to various factors such as increased methio-
nine requirements for fetal growth or changes in endocrine
function(73,74).
Dimethylglycine is a by-product of choline–betaine
metabolism, and also a derivative of glycine(75). Plasma
dimethylglycine levels appear to be lower in pregnant than
in non-pregnant women (by 28%), and higher in fetal
(2.44mmol/l, SE 0.12) compared with maternal plasma
(1.81mmol/l, SE 0.12) as shown in a Canadian study(75).
Methyl donors
Methyl-group donors (also known as lipotropes) are all diet
derived(76). There is growing evidence that methyl donors
are critical during pregnancy and that dietary excess or
deficiency may have an impact on epigenetic programming
in human subjects as in animals. Intake of folate and
choline can be marginal during gestation and mismatch the
biological requirements, leading to maternal depletion of
stores and potentially to clinical deficiency(35). The inter-
actions between methyl donors for biological methylation
and homocysteine removal make it difficult to separate
their individual impact when studying reproductive out-
comes. Furthermore, each of these methyl donors has spe-
cific roles in fetal development.
Folate is a B-vitamin (vitamin B9), indispensable for the
biosynthesis and repair of DNA and is a cofactor of
numerous biochemical reactions(69). Folate functions as a
coenzyme and is key in the transfer of methyl groups(58).
Its function in normal neural tube closure in early gestation
(21–28 d after conception in human subjects) has long
been recognised(77). Maternal supplementation with folic
acid is implemented almost universally for prevention(78)
and in some countries diet fortification has also been suc-
cessful in reducing the incidence of neural tube defects(79).
In human subjects, maternal plasma folate is the main
determinant of transplacental folate delivery to the
fetus(80). Blood folate in the fetus is several-fold higher
than in the mother, and active transport occurs through a
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placental folate receptor. Plasma concentrations of folate
fluctuate according to recent intakes and thus may reflect the
effect of temporary changes in diet; low levels maintained
over time indicate low folate intake and chronic deple-
tion(58). A cut-off point for deficiency of <7 nmol/l has been
advised to prevent negative balance of folate(81), but higher
levels above 16 nmol/l are required to reduce neural tube
defects(82). Pregnancy is associated with an increase in the
demands of folate for fetal and uteroplacental organ
growth(80). Therefore, circulating folate concentrations de-
cline during gestation in women who are not supplemented
with folic acid(83), sometimes leading to overt folate defi-
ciency. Furthermore, low folate in pregnant women does not
appear to result in high plasma homocysteine suggesting
effective homocysteine lowering mechanism(s) during
pregnancy(84).
Choline is classified as part of the B-complex vitamins
group, although it can be synthesised in the body from
phosphatidylethanolamine. This de novo synthesis capa-
city, however, is limited(85). Most men and post-
menopausal women deprived of dietary choline develop
symptoms of deficiency, including fatty liver or muscle
damage(56,86). Conversely, only about 44% of pre-
menopausal women develop such problems in the absence
of dietary choline because endogenous synthesis is upre-
gulated by oestrogen(87). Choline is also involved in the
closure of the neural tube(88,89). Most choline is oxidised
by choline dehydrogenase to betaine to participate in C1
metabolism(90). Choline also has an important function
later in pregnancy during neurogenesis of the fetal hippo-
campus, and deficiency of choline can have on visuospatial
and auditory memory that persist in adulthood(91). Folate
appears to contribute to later brain development like cho-
line and deficiency of either diminishes neurogenesis and
increases neural cell death in the fetal brain(92,93). Addi-
tionally, dietary choline can transform into acetylcholine
for cholinergic neurotransmission, transmembrane signal-
ling and lipid transport and metabolism or into phosphati-
dylcholine and sphingomyelin for cell membrane
constitution and integrity(94).
Adequate levels of choline in plasma have not been
defined as yet. Plasma choline has been reported to be up
to 45% higher in pregnant compared to non-pregnant
women(75,95) probably due to increased endogenous synth-
esis when oestrogen levels rise from 1 nmol/l to up to
60 nmol/l to support the higher demands(35). Large
amounts of choline are delivered to the fetus across the
placenta, through a specific transporter-like protein(96),
which may deplete the maternal stores(97). Choline concen-
tration in amniotic fluid is 10-fold greater than in maternal
blood(98). It has been estimated that about 60% of methyl
groups are derived from choline, 20% from methionine
and 10–20% from folate(76), indicating a central role of
choline as a methyl donor.
Betaine conversion from choline primarily takes place
in the liver and kidney and is irreversible(94). Therefore,
dietary betaine can potentially have a choline-sparing
effect although not for all the functions of choline. Betaine
is also an osmolyte that protects cells from environmental
stress such as drought, high salinity or high tempera-
tures(90). It permits water retention in cells, thus protecting
them from dehydratation. Plasma betaine is highly
variable, in women typically 20–60mmol/l in resting con-
ditions(99). Plasma betaine has been seen to decrease(75)
in the first half of pregnancy, from 16.3 to 10.3mmol/l and
remains constant thereafter(100). High concentrations of
betaine are found in neonates, presumably linked to the
high fetal-choline levels(101).
Methionine is a sulphur-containing amino acid, indispen-
sable because human subjects cannot fix inorganic sulphur
into organic molecules(64). It is the precursor of cysteine.
Cysteine cannot be used to synthesise methionine, but a
derivative of cysteine, cystine, has a methionine-sparing
effect and can replace approximately 70% of dietary
requirements for methionine(102). It has been observed that
women with higher methionine intakes are at lower risk for
neural tube defect affected pregnancies, irrespective of
folate intake(103).
Enzyme cofactors
The main enzymatic cofactors in the C1 metabolism cycle
are the B-vitamins riboflavin, B6 and B12. These are
essential and diet derived. They have all been shown to be
associated with a reduction in neural tube-defect risk(104).
Riboflavin is an integral component of the coenzymes
flavin mononucleotide and flavin-adenine dinucleotide; it
catalyses numerous metabolic redox reactions, including
energy production and production of pyridoxic acid from
pyridoxal (vitamin B6)
(58). During pregnancy the level of
riboflavin carrier proteins in plasma increases, resulting in
a higher rate of riboflavin uptake at the maternal surface of
placenta and thus in transfer towards the fetus(105). One of
the most commonly used indicators for riboflavin status
assessment is the erythrocyte glutathione reductase activity
coefficient. Values of <1.2 have been traditionally con-
sidered to be adequate by representing complete tissue
saturation; 1.2–1.4 is considered as low and >1.4 as defi-
cient(69); however, different cut-offs are often used by
investigators.
Pyridoxine (vitamin B6) and related compounds are
involved, among others, in amino acid, lipid and glycogen
metabolism, and neurotransmitter synthesis(58). They are
absorbed by passive diffusion. A cut-off point of 20 nmol/l
has been proposed for plasma pyridoxal 50-phosphate(69).
In pregnancy, pyridoxal 50-phosphate is lower still in sub-
jects with pre-eclampsia(106).
Cobalamin (vitamin B12) is a cobalt-containing com-
pound necessary for normal blood formation and neurolo-
gical function(69). Vitamin B12 is normally transported by
transcobalamin II, produced in the liver and the placenta.
The transfer from mother to fetus occurs via specific-
receptor carriers(107). Values between 148 and 220 pmol/l
are considered subclinical deficiency of plasma vitamin B12
and values below this, clinical deficiency(82). Levels are
affected substantially by age(58).
Evidence for environmentally induced alterations in
methylation patterns in human subjects
C1 metabolism has been the subject of intense research, but
concrete evidence of its involvement in DOHaD still needs
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to be built up systematically. The Pune Maternal Nutrition
Study cohort in India has provided evidence of the impor-
tance of C1 metabolism in fetal programming
(108–110). Low
maternal levels of vitamin B12 (<150 pmol/l) correlated
strongly with hyperhomocysteine levels (>15mmol/l)(109)
and predicted higher offspring adiposity and higher insulin
resistance(108). High levels of erythrocyte folate predicted
increased body fat and insulin resistance too. Children
from mothers with low vitamin B12 concentrations who
were also folate replete were the most insulin resistant,
possibly due to vitamin B12 disturbance of the methyl-
group transfer for the folate-dependant pathway. The
authors speculated about vitamin B12 trapping folate as
5-methyltetrahydrofolate, thereby preventing the gener-
ation of methionine from homocysteine and potentially
DNA methylation, but this was not tested. Vitamin B12 and
folate status at 18 weeks of pregnancy were more strongly
associated than those at 28 weeks emphasising how critical
these substances are in early-mid pregnancy(108). Interest-
ingly, lower folate and higher plasma homocysteine(110)
were associated with a smaller newborn size suggesting
caution with strategies based only on increasing fetal
growth. Research is moving towards direct assessment of
biomarker exposure(s) instead of employing birth weight
as proxy, as the latter has a multifactorial origin and has
proved to be a poor measure of exposure(111).
While, in recent years, different micronutrient trials
have been conducted(112–114) that included folate and other
cofactors (riboflavin and vitamins B6 and B12), these have
so far only focused on short-term infant and adverse-
pregnancy outcomes. Further investigations into DNA
methylation patterns and longer-term follow up to explore
disease risk will be important.
Comparable findings observed in animals of methyl-
donor maternal supplementation inducing phenotypic
changes mediated by DNA methylation are lacking in
human subjects at present, but it is believed that similar
mechanisms do take place. Some emerging evidence in hu-
man subjects has been provided by observational studies.
Monozygous twins are genetically identical; however,
they can exhibit remarkable differences in susceptibility to
diseases which may be affected by changes to DNA methyl-
ation. Thus, they offer a good opportunity for the study of
epigenetics. Fraga et al.(36) observed that DNA methylation
patterns in twins are indistinguishable at birth. This would
be logical, as they share the same oviduct environment
before implantation and although the nutrient supply might
differ during placentation, it might be too late then to
induce systemic epigenetic differences between twins(8).
Therefore, they are likely to establish very similar DNA
methylation patterns. However, methylation patterns in
twins diverge over their life-time(36), illustrating the plas-
ticity of DNA methylation, probably under environmental
pressure. Divergences can already be observed in early
childhood(115).
Relevant to the DOHaD theory and illustrative of epi-
genetic programming was the first evidence of effects of
the intra-uterine environment on DNA methylation, which
comes from the ‘natural experiment’ of the Dutch Hunger
Winter cohort(116). This famine at the end of the Second
World War provided a setting for the retrospective study of
prenatal exposures: well-documented average daily rations
dipping to 1673.6–3347.2 kJ/d (400–800 kcal/d), and de-
tailed health care data on mothers. Long-term follow-up
studies of individuals conceived during the famine have
shown that prenatal undernutrition is associated with dif-
ferent adverse metabolic phenotypes, such as higher BMI,
elevated serum cholesterol or impaired glucose tolerance
and increased risk for insulin resistance, though this de-
pends on the phase of development at exposure(116). In an
attempt to explain these observations, Heijmans et al.(117)
tested for differences in DNA methylation of the IGF2
gene locus comparing those exposed to periconceptional
famine in early development with same-sex siblings con-
ceived before or after the famine six decades later
(Table 1). The authors found an average decrease of 5.2%
in DNA methylation at this locus, thus suggesting that
transient environmental conditions such as intra-uterine
undernutrition can be recorded as persistent changes in the
epigenome(117). Interestingly, the association was only
found when exposure was periconceptional but not later in
gestation, highlighting the importance of timing of expo-
sure. Steegers-Theunissen et al.(118) also looked at whether
maternal folic acid periconceptional supplementation
affected methylation of insulin-like growth factor 2 show-
ing a 4.5% increase in methylation in individuals whose
mothers had taken folate during early pregnancy.
The same group later tested a set of fifteen additional
candidate genes and reported association of periconcep-
tional undernutrition with DNA methylation for six of the
genes(119). Results for two genes indicated association with
exposure during late gestation, thus suggesting that en-
vironmentally induced methylation changes are not limited
to periconception (Table 1). Some of the associations were
sex-dependent, in line with previous findings in human
subjects(120) and sheep(51). The differences in methylation
were smaller than those seen for the insulin-like growth
factor 2 locus and often showed an increase rather than an
expected decrease in methylation with undernutrition. This
is difficult to explain by deficiency in methyl donors, and
thought to be part of an adaptative response(119). These
studies on the Dutch Hunger Winter cohort suggest that
DNA methylation changes assumed to be established in
early development can be persistent and may be frequent,
but of relative small individual effect, implying that dis-
ease risk might entail a combination of multiple changes(2).
Interestingly, Tobi et al.(121) investigated (using the same
cohort) whether the methylation level at defined loci was
related to intrauterine growth restriction and children small
for gestational age, both being phenotypes commonly used
as measures of fetal environment, and found no associa-
tion(121). The authors concluded that these parameters may
thus be associated with epigenetic changes in other loci not
investigated or to non-epigenetic mechanisms.
To further our understanding in this area, Waterland
et al.(122) set out to identify ME in human subjects. ME are
more likely to be affected by environmental exposures and
are not tissue-specific, which make it easier to analyse ME
in human studies, through use of DNA from readily ac-
cessible peripheral blood samples as opposed to DNA from
specific tissue samples. They designed a genome-wide
methylation-specific analysis to screen for ME. Parallel
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Table 1. Effect of environmental (nutritional) exposure in utero on DNA methylation in human studies
Reference Exposure Timing of exposure Sample size Loci investigated Effect observed
Timing of
DNA-methylation
measurement
Additional
information
Heijmans et al.(117) Famine (Hunger
Winter in
The Netherlands
1944–45)
Average ration:
2790.72 kJ/d,
12% protein
19% fat
69% carbohydrates
Periconception Sixty exposed
Sixty control
IGF2 Hypomethylation at four
CpG sites out of five
Average difference = - 5.2%,
P = 5.9 · 10 - 5
Six decades later Results independent
of sex
Imprinted gene key
in human growth
and development
Late gestation Sixty-two exposed
Sixty-two control
IGF2 No difference at five
tested CpG site
Six decades later
Tobi et al.(119) Famine (Hunger
Winter in The
Netherlands
1944–45)
Average ration:
2790.72 kJ/d
12% protein
19% fat
69% carbohydrates
Periconception Sixty exposed
Sixty control
GNASAS
MEG3
IL-10
ABCA1
LEP
INSIGF
KCNQ1OT1
GRB10
GNASAB
APOC1
IGF2R
FTO
CRH
TNF
NR3C1
1.1%, P = 3.1 · 10 - 6
0.5%, P = 8 · 10 - 3
2.4%, P = 1.8 · 10 - 6
1.7%, P = 8.2 · 10 - 4
1.2%, P = 2.9 · 10 - 3
- 1.6%, P = 2.3 · 10 - 5
NS
NS
NS
NS
NS
NS
NS
NS
NS
Six decades later Sex differences in
methylation
Candidate genes
for metabolic
and CVD
Late gestation Sixty-two exposed
Sixty-two control
GNASAS
LEP
IL-10
INSIGF
KCNQ1OT1
APOC1
IGR2R
CRH
- 1.1%, P = 1.1 · 10 - 7
Difference in men only
(P = 0.017)
NS
NS
NS
NS
NS
NS
Six decades later Sex differences in
methylation
Steeers-Theunisse
et al.(118)
Folic acid
supplementation
intake (The
Netherlands
2003–2007)
4 weeks after
conception to
8 weeks after
delivery
Eighty-six with FA
Thirty-five
without FA
IGF2 4.5%, P = 0.014 Between 12 and
18 months after
delivery
Methylation was
associated with
lower birth weight
Imprinted gene key
in human growth
and development
Waterland et al.(122) Seasonality (rainy
season v. dry season,
The Gambia, 1991,
1994, 1995, 1998)
Conception Twenty-five per
season
BOLA3
FLJ20433
PAX8
SLITRK1
ZFYVE28
LINE1
IGF2
GNASAS
IL-10
>5%, P = 0.03
<5%, P = 0.03
>10%, P = 0.02
<5%, P = 0.006
>10%, P = 0.002
Overall, P = 0.0001
Non-significant
control genes
NS
NS
NS
NS
Age: 8.9 years
(0.5 SEM)
First description of
human ME
aIGF2, insulin-like growth factor 2; CpG, cytosine–guanidine; ME, metastable epialleles.
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screening of DNA from different tissues was used to ex-
clude loci with tissue-specific methylation and discordance
within monozygotic twin pairs provided support that inter-
individual variation in methylation at the identified ME
was stochastic. The establishment of ME in early devel-
opment was then tested by studying differences in DNA
methylation according to season of conception (dry/rainy)
in rural Gambia (West Africa). Rural Gambia experiences
dramatic seasonal fluctuations in food availability and
maternal nutritional status, the rainy season being the most
nutritionally challenged due to the high workload in the
fields and the scarce stocks remaining from the previous
harvest(123). At the five loci investigated (Table 1), con-
ception during the annual rainy season resulted in sig-
nificantly higher DNA methylation, thus providing the first
evidence of environmentally-associated changes in human
ME. It is not clear whether these differences in DNA
methylation in individuals conceived in the dry or the rainy
season are mediated by seasonal differences in the avail-
ability or deficiency of methyl groups in the diet and
maternal nutritional status. The differences in methylation
by season were >10% for several of the loci and thus less
subtle than those observed during the Dutch Hunger Win-
ter studies(117, 119). Since ME affect every cell type, they
are more likely to be relevant to human disease. Notably,
two of the five described genes, namely PAX8 and
SLITRK1, are known to be implicated in hypothyroidism
and Tourette’s syndrome, respectively(122).
Additionally, from the Swedish Overkalix cohort there are
some hints of (male-line) transgenerational responses to
nutrition in human subjects(124). Food supply in adolescence
of paternal grandparents correlated with the grandchild’s
longevity, including associations with risk of cardiovascular
or diabetic death. There is currently no data on the mechan-
ism(s) underlying these observations, however, epigenetic
gametic inheritance may be a possible explanation(22).
From the studies outlined earlier several conclusions can
be drawn. Human ME are likely to be susceptible to early
environmental influences(122). Differential methylation at
other loci (e.g. IGF2, GNASAS or IL-10) (Table 1), not
classified as ME, also appear to be affected by early
nutritional exposures. Attention has to be given not only to
the timing but also to the strength of the exposure. The
Gambian study(122) investigated severe yet ‘physiologi-
cally’ mild differences in exposure as measured by season
(which may or may not reflect maternal status), whereas in
the Dutch studies(117) famine arguably is a more extreme
exposure with regard to establishment of DNA methylation
patterns in early development. It would be interesting to
see whether the findings in Gambians can be reproduced in
The Dutch Hunger Winter setting and whether there might
be greater differences in methylation rate at the ME iden-
tified. Additionally, more data are needed in terms of
accurate measurement of timing, dose and nutrient type(s)
exposure periconceptionally or during pregnancy.
Conclusions
Epigenetics is still a recent and intricate science, where
much is known but even more is yet to be determined.
DNA methylation and other epigenetic mechanisms are
becoming easier to study because of advances in technol-
ogy, with the potential for providing a deeper understand-
ing of complex diseases, even in utero.
There is an increasing body of evidence in animal
models to suggest that many of the observed effects in fetal
programming are mediated by epigenetic changes, but
parallel evidence has to be further developed in human
subjects. Furthermore, critical windows of exposure(s) that
seem to exist during development have to be better
defined, and also the balance between early acquired DNA
methylation patterns as compared with ulterior modifi-
cations during life-course.
It is certainly a challenge to identify genomic regions
that are likely to be more susceptible to methylation
changes in response to prenatal environmental influences
(human ME). Analogous to the development of the
‘Human Genome Project’, the ‘Human Epigenome Project’
aims to identify, catalogue and interpret DNA methylation
patterns of all human genes in all major tissues (http://
www.epigenome.org/). This and other research efforts will
help understand epigenetic processes and their role in dis-
ease pathogenesis.
Redundancy in methyl-donor supply pathways as part of
the C1 metabolism means that changes in the level of one
substance can potentially perturb the others through com-
pensation mechanisms. Therefore, a comprehensive
approach is needed when investigating these substances
and how they affect DNA methylation.
All this needs to be taken into account in the design of
new studies to better understand how maternal diet affects
developmental epigenetics and the possible downstream
consequences. Prospective studies, either observational or
supplementation trials, should be designed, where accurate
maternal nutritional status at specific times during preg-
nancy and the interactions between the different nutrients
can be assessed in relation with DNA methylation. In
addition, it will be important to link such basic research to
measurable health effects in offspring phenotype, thus
children need to be followed-up to ascertain the real
impact of DNA methylation changes established during
early development.
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